These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11842392)

  • 1. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia.
    Nabhan C; Rosen ST
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):75-80. PubMed ID: 11842392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia.
    Nabhan C; Rosen ST
    Semin Oncol; 2002 Feb; 29(1S2):75-80. PubMed ID: 28140095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
    Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T
    Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
    Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH
    Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
    Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Osterborg A
    Blood; 2002 Aug; 100(3):768-73. PubMed ID: 12130484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Robak T
    BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):70-4. PubMed ID: 11842391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia.
    Nabhan C; Dyer MJ; Rosen ST
    Oncology (Williston Park); 2003 Feb; 17(2):253-62; discussion 264, 267, passim. PubMed ID: 12632866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
    Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
    Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody therapy of leukaemias and lymphomas.
    Jacobs SA; Foon KA
    Expert Opin Biol Ther; 2005 Sep; 5(9):1225-43. PubMed ID: 16120052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
    Faderl S; Thomas DA; O'Brien S; Garcia-Manero G; Kantarjian HM; Giles FJ; Koller C; Ferrajoli A; Verstovsek S; Pro B; Andreeff M; Beran M; Cortes J; Wierda W; Tran N; Keating MJ
    Blood; 2003 May; 101(9):3413-5. PubMed ID: 12522009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy for chronic lymphocytic leukemia.
    Quintás-Cardama A; O'Brien S
    Target Oncol; 2009 Jan; 4(1):11-21. PubMed ID: 19343298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
    Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
    J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
    Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody combinations in CLL: evolving strategies.
    Faderl S; O'Brien S; Keating MJ
    Best Pract Res Clin Haematol; 2006; 19(4):781-93. PubMed ID: 16997183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
    Robak P; Linke A; Cebula B; Robak T; Smolewski P
    Leuk Lymphoma; 2006 Dec; 47(12):2625-34. PubMed ID: 17169808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
    Moreton P; Hillmen P
    Semin Oncol; 2003 Aug; 30(4):493-501. PubMed ID: 12939718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
    Alatrash G; Albitar M; O'Brien S; Wang X; Manshouri T; Faderl S; Ferrajoli A; Burger J; Garcia-Manero G; Kantarjian HM; Lerner S; Keating MJ; Wierda WG
    Br J Haematol; 2010 Feb; 148(3):386-93. PubMed ID: 19895616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.